NCT02042014View on ClinicalTrials.gov

Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 22, 2014

Primary Completion Date

October 17, 2016

Study Completion Date

October 17, 2016

Conditions
Severe Pulmonary Arterial Hypertension
Interventions
DRUG

QTI571

QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.

Trial Locations (3)

980-8574

Novartis Investigative Site, Sendai

113-8655

Novartis Investigative Site, Bunkyo-ku

181-8611

Novartis Investigative Site, Mitaka

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY